HOME >> BIOLOGY >> NEWS
Angelman syndrome deficits rescued in mice

Children with Angelman syndrome are often seen laughing and smiling, but this cheerful demeanor masks serious neurological problems mental retardation, movement problems and seizures.

New research in mice, however, suggests that many of these deficits could be alleviated.

Edwin Weeber, Ph.D., and colleagues reversed the neurological deficits in a mouse model of Angelman syndrome by preventing the inhibition of CaMKII, an enzyme highly expressed in brain regions affected by Angelman syndrome.

The results, which appear in the March issue of Nature Neuroscience (currently available online), reveal an important part of the mechanism underlying the condition and point to potential therapeutic targets for treating these symptoms.

Angelman syndrome, which affects approximately one in 15,000 children, is a debilitating neurological disorder characterized by mental retardation, severely limited speech, and movement and balance problems.

In 1997, researchers determined that Angelman syndrome was caused by a mutation in a single gene, called UBE3A. They subsequently developed a mouse model of Angelman syndrome by mutating this gene.

But the finding was baffling, said Weeber, because UBE3A is a "housekeeping" gene, meaning that it broadly regulates cellular processes not particularly specific for any of the neurological deficits seen in these children. Specifically, the protein encoded by UBE3A "tags" other proteins for degradation by the cellular "garbage disposal," the proteasome.

"The most difficult thing to rationalize was that this housekeeping gene which nobody thought did anything caused severe mental retardation," said Weeber, an assistant professor of Molecular Physiology and Biophysics and Pharmacology and senior author on the study.

"So we started trying to identify some of the protein's molecular targets."

In the process, Weeber and colleagues identified an abnor
'"/>

Contact: Melissa Marino
melissa.marino@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
8-Feb-2007


Page: 1 2 3

Related biology news :

1. Unknotting DNA clue to cancer syndrome
2. Metabolic syndrome -- dont blame the belly fat
3. Researchers identify fifth gene responsible for Joubert syndrome
4. Fragile X syndrome -- A stimulating environment restores neuronal function in mice
5. Studies assess effectiveness of serotonin and nerve stimulants on irritable bowel syndromes
6. U of M researchers find new, more effective treatment for toxic shock syndrome
7. Cherries may help reduce metabolic syndrome and heart disease risk factors
8. Cholesterol could be key to treating fetal alcohol syndrome
9. Rare mutation causes early heart disease and metabolic syndrome
10. Shortening chromosomes cause for earlier cancer onset in families with rare syndrome
11. Proteases cause pain in irritable bowel syndrome

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2020)... ... June 25, 2020 , ... ... biopharmaceutical R&D, today announced that it has entered into a multi-year contract ... (Multiclonics®), to support their translational and clinical research strategy to discover and ...
(Date:6/25/2020)... ... June 24, 2020 , ... ... software and software-driven clinical data services that accelerate drug development, is collaborating with ... an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This is the first ...
(Date:6/23/2020)... , ... June 23, 2020 , ... ... sustainable healthcare, and Renovagen Ltd, a UK supplier and manufacturer of innovative portable ... support testing operations in the fight against the COVID-19 pandemic in Zambia. , ...
Breaking Biology News(10 mins):
(Date:5/28/2020)... (PRWEB) , ... May 28, 2020 , ... The ... and security leaders as the 2020 winners of the Women in Biometrics Awards ... sponsors IDEMIA , Biometric Update and the SIA Women in ...
(Date:5/21/2020)... ... , ... Threats to intellectual property, political pressure to lower ... wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new ... commercially weaker, dealing with delays in new product launches and with fewer resources ...
(Date:5/21/2020)... ... ... Eaton Square is pleased to announce its growth on the East Coast of ... strategy and M&A advisory firm. , This is an important step for Eaton Square ... healthcare innovators with capital and investors. , Popper and Company, founded in 2003 by ...
(Date:5/15/2020)... (PRWEB) , ... May 14, ... ... supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC ... to enable streamlined and multi-format collection of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC ...
Breaking Biology Technology:
Cached News: